Period	EPS Est.	Range	Growth	#
Current Q	$-0.32 ▼ -14.5%	$-0.42 — $-0.20	43% YoY	3
Next Q	$-0.38 ▼ -16.5%	$-0.54 — $-0.21	45% YoY	3
Current FY	$-1.16 ▼ -5.8%	$-1.38 — $-0.78	58% YoY	3
Next FY	$-0.95 ▼ -6.1%	$-0.96 — $-0.94	18% YoY	2

Latest Reports

BEARISH 8-K 7/10

Senti Biosciences issued $10.0M in aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SP

May 26, 2026

BULLISH 8-K 7/10

Senti Bio reported Q1 2026 results with net loss of $4.2M ($0.14/share) vs $14.1M ($1.41/share) in Q1 2025, driven by a

May 14, 2026

BULLISH Press 8/10

Senti Bio announced a successful Type B RMAT meeting with the FDA, finalizing a single-arm registrational trial strategy

May 14, 2026

Recent Insider Trades

Date	Insider	Type	Value
Mar 9, 2026	Lu Timothy	F	$0.00
Mar 9, 2026	Rajangam Kanya	F	$0.00
Feb 2, 2026	Rajangam Kanya	F	$0.00
Feb 2, 2026	Lu Timothy	F	$0.00

∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

2 unique insiders with 4 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

Date	Insider	Title	Type	Shares	Price	Value
Mar 9, 2026	Lu Timothy K	CEO	TAX W/H	80,666	—	—
Mar 9, 2026	Rajangam Kanya	Pres. & Chief Med. & Dev. Off.	TAX W/H	10,757	—	—
Feb 2, 2026	Rajangam Kanya	Pres. & Chief Med. & Dev. Off.	TAX W/H	1,384	—	—
Feb 2, 2026	Lu Timothy K	CEO	TAX W/H	4,191	—	—

5 SEC filing reports analyzed. Sentiment: 2 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.8/10.

BEARISH 8-K 7/10

Senti Biosciences issued $10.0M in aggregate principal amount of Senior Secured Convertible Notes to

May 26, 2026

BULLISH 8-K 7/10

Senti Bio reported Q1 2026 results with net loss of $4.2M ($0.14/share) vs $14.1M ($1.41/share) in Q

May 14, 2026

BULLISH PRESS-RELEASE 7/10

Senti Bio reported Q1 2026 EPS of -$0.14, beating consensus of -$0.36 by 61%, on minimal revenue of

May 14, 2026

NEUTRAL 15-12G 2/10

Senti Biosciences, Inc. filed Form 15-12G to terminate its SEC registration following a holding comp

May 8, 2026

BEARISH 424B5 6/10

Senti Biosciences filed a 424B5 prospectus supplement for its existing at-the-market (ATM) equity of

May 1, 2026

BULLISH 8/10

Senti Bio announced a successful Type B RMAT meeting with the FDA, finalizing a single-arm registrat

May 14, 2026

MIXED 6/10

Senti Biosciences reported Q4 and full-year 2025 financial results, showing a narrowed net loss comp

Mar 27, 2026

Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 3 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$11.25 mean target +1071.6% upside Strong Buy (3.00)

$6.00 Low $15.00 High

Metric	Value
Current Price	$0.9602
Target Low	$6.00
Target Mean	$11.25
Target Median	$12.00
Target High	$15.00
# Analysts	4
Recommendation	Strong Buy (3.00)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-06-30	$-0.32	$-0.42	$-0.20	43.5%	-14.5%	—	$0.0B	0.0%	3
Next Q 2026-09-30	$-0.38	$-0.54	$-0.21	45.4%	-16.5%	—	$0.0B	0.0%	3
Current FY 2026-12-31	$-1.16	$-1.38	$-0.78	57.6%	-5.8%	—	$0.0B	51.5%	3
Next FY 2027-12-31	$-0.95	$-0.96	$-0.94	17.9%	-6.1%	1↑ 0↓	$0.0B	50.0%	2

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.317
7d ago	$-0.277	-0.040
30d ago	$-0.277	-0.040
60d ago	$-0.310	-0.007
90d ago	$-0.310	-0.007

1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
May 15, 2026	Chardan Capital	MAINTAIN	Buy	Buy
Mar 30, 2026	Chardan Capital	MAINTAIN	Buy	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	3	6	1	90%
May 1, 2026	3	6	1	90%
Apr 1, 2026	3	6	1	90%
Mar 1, 2026	3	6	1	90%
Feb 1, 2026	3	6	1	90%
Jan 1, 2026	3	6	1	90%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 14, 2026

earnings

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm p

May 14, 2026

fda

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-20

May 6, 2026

earnings_calendar

SNTI Q1 2026 Earnings Scheduled — 2026-05-06

Apr 1, 2026

routine

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

SOUTH SAN FRANCISCO, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-

Mar 27, 2026

earnings

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

SOUTH SAN FRANCISCO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-

Mar 23, 2026

other

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-

Mar 18, 2026

earnings_calendar

SNTI Q4 2025 Earnings After Market Close — 2026-03-18

Mar 3, 2026

other

Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-